한국어
Home › US companies › Charles River Laboratories International

Charles River Laboratories International

CRL · NYSE · Services-Commercial Physical & Biological Research
Insider buys (12 months)
$7,338
Insider sales (12 months)
$52.1M
8-K reports (12 months)
12
Tracked investors holding
0

At a glance

Charles River Laboratories International reported 2025 revenue of $4.02B, down 0.9% from $4.05B in 2024. Over 4 years since 2021 ($3.54B), that is growth of about 3.2% a year. Operating margin was 0.6%, down from 16.7% in 2021. Revenue peaked in 2023 at $4.13B.

In the last 12 months 8 insiders reported 2 open-market purchases ($7,338) and 14 sales ($52.1M). 10 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $16.9M by Director James C Foster on Jul 1, 2026. Net, insiders were sellers of $52.1M.

Charles River Laboratories International filed 12 current reports (Form 8-K) in the last 12 months, most often for results of operations (5), regulation fd disclosure (3), officer or director change (3) and shareholder vote results (1). The latest officer or director change was reported on May 11, 2026.

Annual results

2021
Revenue $3.54B
Op. $589.9M
2022
Revenue $3.98B
Op. $651M
2023
Revenue $4.13B
Op. $617.3M
2024
Revenue $4.05B
Op. $227.3M
2025
Revenue $4.02B
Op. $25.2M
RevenueOperating income (or net income)SEC XBRL annual filings, fiscal years mapped to calendar years
Year20212022202320242025
Net income$391M$486.2M$474.6M$22.2M-$144.3M
Diluted EPS$7.60$9.48$9.22$0.20$-2.91

Fiscal year ends Dec 27

Current reports (8-K, last 12 months)

09/24Regulation FD disclosure2026
08/05Results of operations2026
05/11Officer or director change · Shareholder vote results2026
05/07Results of operations2026
02/25Regulation FD disclosure2026
02/18Officer or director change2026
02/18Results of operations2026
01/13Results of operations2026
01/09Officer or director change2026
12/03Regulation FD disclosure2025
11/17Other events2025
11/05Results of operations2025

Insider open-market trades (last 12 months)

10/26Sale10b5-1Director James C Foster sold 24,042 sh at $350.00, Oct 22.$8.4M
10/23Sale10b5-1CEVP, Disc & Safety Assessment Shannon M Parisotto sold 2,156 sh at $344.41, Oct 21.$743K
10/7Sale10b5-1CEVP, Disc & Safety Assessment Shannon M Parisotto sold 981 sh at $308.44, Oct 5.$303K
10/2BuyEVP & Chief Financial Officer Glenn Coleman bought 10 sh at $297.43, Sep 30.$2,974
8/27Sale10b5-1Director James C Foster sold 33,561 sh at $300.00, Aug 25.$10.1M
8/20Sale10b5-1CEVP, Disc & Safety Assessment Shannon M Parisotto sold 2,039 sh at $294.12, Aug 19.$600K
8/20SaleDirector Nancy C Andrews sold 573 sh at $285.24, Aug 18.$163K
8/13Sale10b5-1Chief Executive Officer Birgit Girshick sold 6,500 sh at $279.90, Aug 11.$1.8M
8/13Sale10b5-1CEVP, Disc & Safety Assessment Shannon M Parisotto sold 3,714 sh at $279.66, Aug 11.$1M
8/11Sale10b5-1Director James C Foster sold 28,733 sh at $275.00, Aug 10.$7.9M
8/10SaleSVP, Finance and CAO Michael Gunnar Knell sold 6,645 sh at $260.38, Aug 6.$1.7M
8/10SaleEVP & Chief People Officer Victoria L Creamer sold 4,179 sh at $259.16, Aug 6.$1.1M
8/6Sale10b5-1CEVP, Disc & Safety Assessment Shannon M Parisotto sold 5,046 sh at $263.00, Aug 5.$1.3M
7/1Sale10b5-1Director James C Foster sold 75,000 sh at $225.00, Jun 29.$16.9M
3/4BuyEVP, Corp Strategy & Develop Joseph W Laplume bought 25 sh at $174.54, Mar 3.$4,364
1/20SaleEVP, Corp Strategy & Develop Joseph W Laplume sold 400 sh at $163.72, Aug 22.$65K

Source: SEC EDGAR. How figures are combined